Articles tagged with Cancer Patients
Researchers found significant disparities in quality of care and outcomes for patients with metastatic pancreatic cancer. Patients with higher social vulnerability indices were less likely to receive guideline-concordant systemic therapy, palliative care, or survive over 12 months.
Novel biomarkers like miRNA-34a link anthracyclines to cardiotoxicity, while stem cell therapy and nanotechnology offer potential for prevention and treatment. Traditional strategies have limitations, but new approaches hold hope for improved patient outcomes.
A new clinical trial at the University of Miami Miller School of Medicine is testing a novel combination of immunotherapy drugs and an oncolytic virus to treat high-grade neuroendocrine cancer. The trial aims to find safe combination doses and compare effectiveness with standard-of-care treatment.
A new editorial in Oncotarget discusses how artificial intelligence can improve liver imaging by recognizing when it might be wrong. The approach, called 'uncertainty quantification,' helps clinicians better detect liver cancer and other diseases by pointing out areas in medical scans that need a second look.
A UCLA study validates the predictive power of PROSTOX, a genetic test that uses microRNAs to identify patients at higher risk of developing long-lasting urinary side effects from radiation therapy. The test helps doctors and patients choose safer treatment options, reducing the burden of long-term complications.
A new study found that blocking an enzyme called HPGDS may be a way to improve melanoma treatment for patients who don't respond to immunotherapy. The enzyme promotes tumor growth and metastasis dissemination by blocking T-cell activity, but blocking it boosts the immune response.
The new tool has the potential to improve cancer survival rates and patient quality of life worldwide by allowing for more targeted and less invasive surgeries. Researchers are currently developing a fully functional prototype that can be trialled in large animal models before progressing to human clinical trials.
A Phase I trial demonstrates AFM13-NK cells are safe and highly effective in heavily pretreated patients with refractory CD30-positive lymphomas, achieving an overall response rate of 92.9% and complete response of 66.7%. The treatment was well-tolerated, with no cases of cytokine release syndrome or graft-versus-host disease.
A Phase 3 trial found that ChemoID improves objective response rates, median progression-free survival, and duration of response in patients with recurrent platinum-resistant ovarian cancer. The test identifies effective treatments by challenging cancer stem cells against specific anticancer drugs.
A new case report presents a highly unusual combination of two benign ovarian tumors: serous cystadenofibroma and collision lesions. Accurate preoperative diagnosis is critical for effective treatment planning, and this case emphasizes the need for personalized evaluation of each ovarian mass.
A federally funded study by Huntsman Cancer Institute found that 7% of Medicare patients with cancer cross state borders for treatment, with rates nearly double for rural patients. Telehealth can fill gaps in cancer treatment and reduce travel burdens, says senior author Tracy Onega.
The new Keck Medicine of USC – Newport Beach Radiation Oncology and Imaging Center offers biology-guided radiation therapy, using up-to-the-minute signals to track and treat cancer cells in real time. The center is equipped with state-of-the-art technology and will be the first in Orange County to provide this treatment option.
The National Comprehensive Cancer Network (NCCN) has awarded four early-career oncologists with $150,000 in funding to tackle pressing challenges in cancer care. The recipients will support studies aiming to improve cancer outcomes through molecular residual disease-guided adjuvant therapy and electronic symptom monitoring.
Researchers discovered that a high-fat diet activates mechanisms facilitating breast cancer metastasis by promoting platelet activation and fibronectin expression, creating a fertile breeding ground for tumor cells to take root. This study provides new insights into the relationship between obesity and breast cancer spread.
The NCCN 2025 Annual Conference showcased the critical impact of cancer research on improving lives. The conference featured new research, discussions on AI in oncology care, and strategies for ensuring high-quality, person-centered cancer care.
A new study suggests that blood cancer patients receiving Bruton Tyrosine Kinase inhibitors should continue their therapy while getting vaccinated against COVID-19. The IMPROVE trial found no improvement in antibody responses when BTKi therapy was paused for three weeks around the time of vaccination.
The University of Rochester's Wilmot Cancer Institute has been named the nation's 73rd designated cancer center by the National Cancer Institute. This prestigious designation recognizes the institute's excellence in cancer research, patient care, and community outreach.
A new study has found that a lower dose of the blood-thinning medication apixaban is as effective as the full dose in preventing recurring blood clots in patients with active cancer. Patients who received the lower dose experienced fewer bleeding complications and similar VTE recurrence rates compared to those on the standard dose.
A single-center retrospective study analyzed clinical data, imaging, histopathological manifestations, genetic testing results, and treatment effects in 48 WD patients. The study found age at diagnosis, K-F ring presence, and higher immunoglobulin G levels were associated with cirrhosis risk factors.
A study published in Plastic and Reconstructive Surgery reports that breast-conserving therapy, including radiation therapy, leads to progressive breast volume loss over time. Women with larger breasts experience greater total breast shrinkage, highlighting the need to discuss long-term changes in breast volume with patients.
Researchers at MD Anderson Cancer Center made several key discoveries, including the spatial organization of cancer-associated fibroblasts across various cancers and a study on treatment resistance in SMARCA4-mutant lung cancer. These findings highlight the importance of investigating cell populations in their spatial context to better...
Researchers developed a personalized app that tracks users' circadian rhythms and provides behavioral recommendations to reduce daily fatigue. The app, called Arcasync, was tested on 138 participants with breast, prostate, and blood cancer, resulting in decreased fatigue and improved quality of life.
Researchers discovered TBX2 drives therapy resistance by shifting signaling from the androgen receptor to the glucocorticoid receptor. The study identified a strategy to target this switch, potentially predicting patient risk and offering new treatment approaches.
The FDA has approved cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumors. The drug showed improved efficacy in reducing tumor growth and improving patient survival compared to placebo.
A new review highlights how breast cancer cells change their communication and growth patterns, helping tumors survive, spread, and resist treatment. The review explores disrupted signaling pathways, including PI3K/Akt/mTOR and RAS/RAF/MEK/ERK, which can promote tumor progression and resistance to treatment.
A single-arm trial evaluated the safety and efficacy of first-line camrelizumab, apatinib, and chemotherapy in untreated extensive-stage small-cell lung cancer patients. The treatment demonstrated an ORR of 88.9% and median PFS and OS of 7.3 and 17.3 months, respectively.
Researchers have developed a TIM-3 decoy that improves the effectiveness of CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia. The decoy blocks the interaction between the tumor and immune cells, allowing CAR-T cells to persist and attack cancer cells more effectively.
Patients with hormone receptor-positive and HER2-negative breast cancers face a higher risk of death from the cancer if they wait more than 42 days after diagnosis to have surgery. Delayed surgery increases the patient's risk exponentially, with risks of death increasing by 21%, 79%, and 183% at 60, 90, and 120 days, respectively.
A study published in the British Journal of General Practice found a significant link between chest x-ray referrals and earlier lung cancer diagnosis and better survival rates. Patients attending practices with high chest x-ray usage were more likely to be diagnosed at an earlier stage, leading to improved survival rates.
A simple urine test has shown promising results in detecting early-stage kidney cancer recurrence, with a high sensitivity and specificity rate. The GAGome test can accurately identify patients at risk of recurrence, potentially reducing the need for invasive scans and enabling faster treatment access.
A TB vaccination has been shown to boost the immune system of bladder cancer patients, reducing cancer recurrence rates by up to 75% in a small pilot study. The vaccine was well-tolerated with no side effects and showed promising results in improving patient outcomes.
New leukemia treatment combination shows promise for patients with follicular lymphoma. Immunotherapy research also explores ways to suppress protein ZNF638 to boost effectiveness of immune checkpoint inhibitors. Innovative funding efforts support Sylvester's cancer research initiatives.
Researchers at Dana-Farber Cancer Institute have identified a potential targeted therapy, avapritinib, for pediatric high-grade gliomas. The treatment resulted in tumor reduction and clinical improvement in 3 out of 7 patients with this currently incurable form of brain cancer.
Patients from American Indian and Black communities are less likely to have elevated CA-125 levels at diagnosis, suggesting current thresholds may miss diverse patients. Inclusive diagnostic guidelines are needed to address disparities in ovarian cancer diagnosis and treatment.
A comprehensive review of studies reveals that over 15% of caregivers of adult cancer patients suffer from post-traumatic stress disorder (PTSD). Caregivers with pre-existing mental health conditions and high caregiver burden are at greater risk. The study highlights the urgent need for proactive screening and support to prevent long-t...
Researchers found that detectable mutant KRAS circulating tumor DNA (ctDNA) indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma. The study suggests that ctDNA assays should be performed prior to treatment to have the highest yield.
Dr. Owen Witte has been awarded the 12th annual Harrington Prize for Innovation in Medicine for his groundbreaking work on leukemia, lymphoma, and other cancers. His discoveries have led to life-saving therapies like Gleevec and ibrutinib, transforming cancer treatment.
This cohort study found that geographic access to cancer care is associated with guideline-recommended treatment for early-stage non–small cell lung cancer. Socially marginalized patients benefited from improved treatment outcomes and prognosis when accessing care in their local area.
Researchers developed an AI tool called Unfold AI to accurately estimate prostate tumor volume and identify patients likely to benefit from partial gland cryoablation. This approach shows promise in reducing treatment failures by over 70% and improving patient outcomes.
A new study confirms that a shorter, higher-dose-per-day radiation course is as effective as conventional radiotherapy for treating early-stage prostate cancer without increasing side effects. The study found similar cancer control rates and fewer gastrointestinal issues with the new approach.
Breast cancer survivors experience accelerated aging due to detrimental effects of BC and its treatments, particularly systemic therapies. The study highlights the need for ongoing monitoring and potential strategies to slow down aging in cancer survivors.
The WIN Consortium is transforming cancer care through personalized medicine, leveraging AI, molecular profiling, and clinical trials. The organization's innovations, including N-of-1 clinical trials and WINTHER and WINGPO trials, are helping clinicians make more precise treatment decisions and improving outcomes for cancer patients.
Researchers found that suppressing ZNF638 triggers an antiviral immune response in glioblastoma patients, making them more susceptible to treatment. This finding offers a potential new treatment strategy for the disease, which has remained challenging despite recent advances in immunotherapy.
The ASCOLT trial found that aspirin does not statistically improve disease-free survival for all patients but demonstrates a consistent trend of improving overall and disease-free survival. Aspirin taken for up to 3 years is efficacious in patients with PIK3CA mutation, reducing recurrence by over 50%.
A combination therapy of FTH-001 (serabelisib) and FTH-003 (sapanisertib) with paclitaxel is being investigated in a Phase 2 trial for patients with advanced or recurrent endometrial cancer. The trial aims to target the PI3K/AKT/mTOR pathway, which is frequently mutated in cancer.
A team of researchers from Chiba University has developed a novel radioactive drug that targets and treats metastatic melanoma. The treatment utilizes astatine-211 labeled peptide analog, which shows high accumulation in tumors, rapid clearance from non-target organs, and significant tumor suppression.
Recent research suggests that some invasive cancers diagnosed in early-stage breast cancer may not need immediate surgery, highlighting the importance of more precise screening methods for DCIS. The COMET trial found that at least half of invasive breast cancers take years to progress or may never progress at all.
Researchers at MD Anderson have made significant breakthroughs in understanding pancreatic cancer's evolutionary process and developing new treatment strategies. They also discovered that surgical resection can enhance antitumor response in patients receiving immune checkpoint therapy for advanced kidney cancer.
Researchers found that pancreatic cancer cells gain a survival edge by carrying copies of critical cancer genes on circular pieces of DNA outside chromosomes. The discovery highlights the importance of targeting extrachromosomal DNA in treating the disease.
A new type of antibody that stimulates the immune system to target cancer cells has shown promise in reducing tumor growth in treatment-resistant breast and ovarian cancers. The study found that the antibody, IgE, uniquely stimulated otherwise inactive immune cells to directly target HER2-expressing cancer cells.
A new drug formulation called Rhenium Obisbemeda has been shown to significantly extend the median survival and progression-free time of glioblastoma patients, with a median overall survival time of 17 months. The treatment, which uses convection-enhanced delivery, shows promise as a potential cure for this deadly brain tumor.
A recent study by Professor Mamas highlights the significant risk of cardiovascular diseases (CVD) in patients with cancer, particularly in aging populations. The review emphasizes the need for early diagnosis and regular monitoring to improve quality of life.
Researchers are conducting a clinical trial to find the optimal combination of pain management tools for patients undergoing mastectomy procedures. The study will enroll approximately 100 patients and examine various combinations of pectoralis nerve blocks, non-opioid analgesics, and administration methods.
Researchers create microfluidic device to sort tumor cells based on adhesive strength, revealing potential method to predict aggressive cancer behavior. The study's findings offer a promising approach for personalizing treatment plans and identifying high-risk patients.
Breast and colorectal cancer screening rates have recovered from pandemic-related declines, surpassing pre-pandemic estimates. Cervical cancer screening rates remain below pre-pandemic levels, indicating a persistent trend of declining early-stage diagnoses.
A new study published in the European Journal of Preventive Cardiology found that a type of diabetes medication called SGLT2 inhibitors can significantly lower the risk of heart failure and hospital visits related to heart failure in cancer patients. The benefits were particularly promising for breast cancer patients receiving anthracy...
Targeted alpha therapy shows promise in treating resistant NETs, offering a precision tool for patients exhausted by conventional treatments. Early preclinical trials have delayed tumour growth with minimal toxicity, while clinical studies have reported high disease control rates.
A new federal mandate aims to improve patient awareness about breast density, which affects cancer detection and risk. Women with dense breasts may need supplemental screening, such as MRI, to detect breast cancer earlier, but this comes with potential downsides.
Researchers have developed a specialized nanoscale material that illuminates cancer cells under freezing conditions, improving surgical precision. This technology enhances surgeons' ability to detect and remove cancer cells during cryosurgery.
A new study reveals that radiotherapy has opposite effects on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), with GBM patients living longer after treatment. The study highlights the need for personalized treatment approaches based on genetic and molecular characteristics to improve survival outcomes.